Treatment
Glucagon-like peptide-1 receptor agonists clinical trials
We’re tracking 15 recruiting studies that include Glucagon-like peptide-1 receptor agonists, each written for real people, not researchers, below.
Recruiting studies
- NCT07575399RecruitingPhase 3
Switching to a New Weight-Loss Medication From Current GLP-1
This trial tests whether switching from your current GLP-1 medication (like Ozempic or Wegovy) to a new drug called maridebart cafraglutide works as well or better for weight management. You must have already lost at least 10% of your body weight on your current GLP-1 and be doing well with it.
Pelham, AlabamaAges 18–99 - NCT07319286Enrolling by invitationPhase 1/Phase 2
GLP-1 drug for period problems in teens with type 1 diabetes
This trial tests whether a GLP-1 receptor agonist can help improve irregular periods in teenage girls with type 1 diabetes. It's for girls aged 12 to 18 who have had their period for at least 2 years, use a continuous glucose monitor, and have higher blood sugar levels (HbA1c of 7% or more).
Cairo, Cairo GovernorateAges 12–18 - NCT07702461Recruiting
Resistance training survey for people on weight loss meds
This trial is an online survey to understand how people taking GLP-1 medications (like Ozempic or Wegovy) are doing with resistance training. If you're an adult on a stable dose of a GLP-1 med for weight or diabetes, your input can help shape better exercise advice.
Columbus, OhioAges 18 years+ - NCT06461377RecruitingPhase 4
GLP-1RA for heart nerve damage in type 2 diabetes
This trial tests whether a type of diabetes medicine called GLP-1RA can help prevent or improve nerve damage in the heart caused by diabetes. It is for people with type 2 diabetes who are overweight or obese.
Nanjing, JiangsuAges 18–70 - NCT06582875RecruitingPhase 2
GLP-1 drug for polycystic kidney disease and weight
This study tests a GLP-1 receptor agonist (a type of medicine that helps with weight and metabolism) in people with polycystic kidney disease who are overweight. It aims to see if this drug can help slow kidney disease progression.
Aurora, ColoradoAges 18–65 - NCT06666049Recruiting
Ultrasound test on the stomach before surgery in patients taking GLP-1 drugs
This trial uses a stomach ultrasound (called gastric POCUS) to check if your stomach is empty before surgery. It is for patients taking GLP-1 medications (like Ozempic, Wegovy, or similar) to help make sure it is safe to proceed with anesthesia.
Madrid, MadridAges 18–90 - NCT06774079RecruitingPhase 4
GLP-1 drug and diet study for Crohn's disease patients
This study tests a drug that helps with weight loss and blood sugar (called a GLP-1 receptor agonist) combined with a special diet to see if it can improve symptoms in people with mild Crohn's disease. You may join if you have Crohn's, a BMI of 27 or higher, and are already on a stable dose of a TNF blocker.
Miami, FloridaAges 18 years+ - NCT07169136Recruiting
GLP-1 medicine for PCOS in teens with obesity
This trial tests if a medicine called a GLP-1 agonist (like semaglutide) can help with hormone and ovulation problems in adolescent girls with PCOS and obesity. It aims to improve irregular periods and other PCOS symptoms.
Jacksonville, FloridaAges 12–18 - NCT07224880Recruiting
Skin tightening and wrinkle treatment study for adults 30-65
This trial tests a micro-coring device called Ellacor® to improve both facial wrinkles and abdominal skin looseness. It is open to people of all skin types and includes those taking certain diabetes/weight-loss medications (GLP-1 agonists).
Dublin, CaliforniaAges 30–65 - NCT07497399RecruitingPhase 2
Testing a diabetes drug for weight loss in MS
This trial tests if a GLP-1 receptor agonist can help people with multiple sclerosis who have a high BMI. It may reduce inflammation and improve health.
Baltimore, MarylandAges 18–60 - NCT07444203Recruiting
Study of kidney tissue in diabetes-related kidney disease
This study collects and studies kidney tissue (from a biopsy or surgery) from people with diabetes-related kidney disease to learn more about the condition. You may be able to help if you've already had a kidney biopsy or certain kidney surgeries.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07140289Enrolling by invitation
GLP-1 drugs and stomach emptying before surgery
This study looks at how GLP-1 medications affect the time it takes for your stomach to empty before anesthesia. It may help doctors decide if you need to take special precautions before your surgery.
Detroit, MichiganAges 18–90 - NCT06924697Enrolling by invitation
Testing a diabetes drug to help men quit smoking
This study tests if a medication used for type 2 diabetes (GLP-1 receptor agonists) can also reduce smoking in men with diabetes who smoke. If you qualify, you may receive this drug or a standard diabetes pill to see if it helps you smoke less.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06581120Enrolling by invitation
Stomach ultrasound study for diabetes and obesity
This study uses ultrasound to see how GLP-1 RA medications (like Ozempic) affect the stomach in people with type 2 diabetes and obesity. It may help doctors better understand how these medicines work.
Cincinnati, OhioAges 10–25 - NCT07288138RecruitingPhase 2
Study of a New Drug for MASH (Fatty Liver Disease)
This study is testing a new drug that targets thyroid hormone receptors in the liver, alone or combined with another drug, to reduce inflammation and scarring in people with MASH (a type of fatty liver disease). If you have MASH with moderate liver scarring and are otherwise healthy, this trial may help find a new treatment option.
Chandler, ArizonaAges 18–75
What Glucagon-like peptide-1 receptor agonists is being studied for
Conditions with recruiting Glucagon-like peptide-1 receptor agonists studies.
Common questions
- Are there clinical trials studying Glucagon-like peptide-1 receptor agonists?
- Yes. Clin2 currently lists 15 recruiting studies that include Glucagon-like peptide-1 receptor agonists, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Glucagon-like peptide-1 receptor agonists trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Glucagon-like peptide-1 receptor agonists an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Glucagon-like peptide-1 receptor agonists or a specific trial is right for you.
Related treatments
- GLP-1 Receptor Agonists
- Multi-peptide CMV-Modified Vaccinia Ankara Vaccine
- Angiotensin Receptor Blockers
- Cytokine-Induced Memory-like Natural Killer Cells
- Glucagon
- Neoantigen-based peptide vaccine
- Chimeric Natural Killer Receptor Universal T-cells
- Neoantigen Peptide Vaccine
- T cell injection targeting CD7 chimeric antigen receptor
- chimeric antigen receptor gene modified T cells
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.